Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Core Viewpoint - Catalyst Pharmaceutical (CPRX) has seen a 14.7% increase in share price over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Group 1: Earnings and Estimates - Estimates for Catalyst Pharmaceutical have trended upward, with a consensus estimate shift of 10.87% in the past month [2] - The stock has a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Group 2: VGM Scores - Catalyst has a strong Growth Score of A but is lagging in Momentum Score with an F, while holding a B grade in value, placing it in the second quintile for this investment strategy [3] Group 3: Industry Performance - Catalyst is part of the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals (IONS) has gained 1.2% over the past month, reporting revenues of $227 million, a year-over-year decline of 30.2% [5] - Ionis Pharmaceuticals is expected to report a loss of $1.07 per share for the current quarter, reflecting a year-over-year change of -9.2%, with a Zacks Rank of 3 (Hold) and a VGM Score of F [6]